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Fatty acid amide hydrolase
Aims: To investigate the local antinociceptive effect as well as the possible mechanisms of action of a novel
analogue of palmitoylethanolamide (PEA) N-(4-methoxy-2-nitrophenyl)hexadecanamide (HD) in the rat
formalin test.
Main methods: The formalin test was used to assess the antinociceptive activity of HD in vivo. The hydrolysis
of anandamide catalyzed by fatty acid amide hydrolase (FAAH) was used to determine the action of HD on
FAAH activity in vitro.
Key findings: Local peripheral ipisilateral, but not contralateral, administration of HD (10–100 μg/paw) produced
a dose-dependent antinociceptive effect in rats. The CB1 and CB2 receptor antagonists AM281 (0.3–30 μg/paw)
and SR144528 (0.3–30 μg/paw), respectively, reduced the antinociceptive effect of HD (100 μg/paw). In addition,
methiothepin (0.03–0.3 μg/paw) and naloxone (5–50 μg/paw) significantly reducedHD-induced antinociception
(100 μg/paw). In vitro, HD reduced only to a minor extent the hydrolysis of anandamide catalyzed by FAAH.
Significance: HD local administration produces antinociception that probably results from an indirect activation
of peripheral CB1 and CB2 cannabinoid receptors. Data suggest that 5-HT1 and opioid receptors also participate
in the antinociceptive effect of this compound. HD may have potential as analgesic drug.© 2012 Elsevier Inc. All rights reserved.Introduction
There is considerable evidence showing that cannabinoid receptor
agonists have analgesic activity in rodent models of inflammatory
(Smith et al., 1998; Farquhar-Smith et al., 2002; Kehl et al., 2003) and
neuropathic (Bridges et al., 2001; Scott et al., 2004) pain. These effects
are mediated via both CB1 and CB2 cannabinoid receptors (Fox et al.,
2001; Scott et al., 2004). However, there is a need to improve the thera-
peutic index of existing cannabinoids, particularly with respect to
short-term motor and psychotropic side effects and the longer-term
risk of psychosis associated with Cannabis use, which are mediated by
CB1 cannabinoid receptors expressed in brain. One approach is to in-
crease the tonus of the endogenous cannabinoid (endocannabinoid)
system indirectly, for example by inhibiting the metabolism of the
endocannabinoid ligands anandamide (AEA, structure shown in Fig. 1)
and 2-arachidonoylglycerol (2-AG). Compounds with this mechanism,
for example, inhibitors of the AEA hydrolytic enzyme fatty acid amidebiología, Cinvestav, Sede Sur.
55 5483 2863.
ados-Soto).
rights reserved.hydrolase (FAAH), are effective in animal models of pain (see e.g.
Lichtman et al., 2004; Chang et al., 2006; Karbarz et al., 2009). Another
approach is to administer the drugs locally in the site of injury.
Palmitoylethanolamide (N-(2-hydroxyethyl)hexadecanamide; PEA,
structure shown in Fig. 1) is an endogenous compound structurally re-
lated to AEA that produces potentially useful effects upon pain and in-
flammation in animal models (Jaggar et al., 1998; Calignano et al.,
1998, 2001; Conti et al., 2002; Quartilho et al., 2003; Johanek and
Simone, 2004; LoVerme et al., 2006; Gutiérrez et al., 2007) and possibly
inman (Calabrò et al., 2010; Conigliaro et al., 2011). Although PEAhasno
direct effects upon CB receptors, its antinociceptive effects involve the
endocannabinoid system, possibly as a result of its action as a competing
substrate at FAAH (Lambert et al., 2002). The ability of PEA to activate
the peroxisome proliferator-activated receptor α (PPARα) pathway
has also been proposed to be involved in its anti-nociceptive and anti-
inflammatory effects (LoVerme et al., 2005, 2006).
The lack of direct effect of PEA upon CB cannabinoid receptors to-
gether with its antinociceptive properties makes it an attractive mole-
cule for the design of novel analogues. In this regard, PEA, which acts
in vitro reduce AEA metabolism (Vandevoorde et al., 2003), has been

















Fig. 1. Chemical structures of N-(4-methoxy-2-nitrophenyl)hexadecanamide (HD) and palmitoylethanolamide (PEA). The structure of the endocannabinoid homologue ananda-
mide (AEA) is shown for comparative purposes.
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temic administration of N-(4-metoxy-2-nitrophenyl)hexadecanamide
(HD, structure shown in Fig. 1), a novel analogue of PEA, inhibits acetic
acid-induced and thermal nociception in mice (Déciga-Campos et al.,
2007). Here, we report the analgesic activity of HD in vivo after local ad-
ministration in the formalin test of persistent pain. In addition, the
mechanisms of action of HD on in vivo and in vitro were investigated.
Materials and methods
Chemical synthesis of HD
A mixture of 4-methoxy-2-nitroaniline (5 g, 0.0297 mol), triethy-
lamine (3.3 g, 0.0327 mol, 1.1 eq) and methylene chloride (50 ml)
was stirred for 30 min. After this time, palmitoyl chloride (8.9 g,
0.0327 mol, 1.1 eq), was added dropwise to the solution. The mixture
was stirred 5 h under nitrogen atmosphere at room temperature. Thin
layer chromatography was used to monitor the reaction. After cooling,
the mixture was neutralized with saturated NaHCO3 solution and the
precipitate formedwasfiltered by suction. The crude productHDwas pu-
rified by recrystallization from ethanol yielding 9.96 g (83%) of yellow
crystals with a melting point of 77.5–78.9 °C. Fig. 1 shows the chemical
structure HD. The compound was fully characterized by 1H and 13C nu-
clear magnetic resonance spectroscopy and also by mass spectrome-
try. 1H NMR (300 MHz, CDCl3),δ 0.80 (t, 3H, CH3), 1.22–1.62 (m, 28H,
CH2), 2.26 (t, 2H, CH2), 3.83 (s, 3H, CH3O), 7.20 (dd, 1H, H-5), 7.41 (d,
1H, H-3), 7.77 (dd, 1H, H-6), 13.21 (s, 1H, NH);13C NMR (75.5 MHz,
CDCl3),δ 14.3 (CH3), 28.1 (CH2), 29.8 (CH2), 29.5 (10 CH2), 29.8
(CH2), 37.3 (CH2-CO), 56.1 (CH3-O), 108.7 (C-3), 123.6 (C-6), 124.1
(C-5), 127.9 (C-1), 136.9 (C-2), 155.1 (C-4), 171.1 (C=O) PPM and
MS: m/z (% relative intensity) 406 (M+, 98), 168 (100); High resolu-




Female Wistar and Sprague–Dawley (180–200 g) rats were used in
this study for behavioral and in vitro experiments, respectively. All exper-
iments followed the Guidelines on Ethical Standards for Investigation of
Experimental Pain in Animals (Zimmerman, 1983) and their care were
conducted in conformity with Mexican Official Norm for Animal Care
and Handing (NOM-062-ZOO-1999). Protocols were approved by the
ethics committee of Cinvestav (Mexico, D.F.) and Umeå University
(Sweden). Efforts were made to minimize animal suffering and to re-
duce the number of animals used. Rats were used once only. Theywere given free access to standard chow and tap water. Animals were
housed in a climate controlled room with a 12 h light/dark cycle. At
the end of the experiment, animals were killed in a CO2 chamber.
Formalin test
The procedure used has been described previously (Rocha-González
et al., 2005). Rats were placed in an open Plexiglass observation cham-
bers for 30 min to allow them to accommodate their surroundings,
then they were removed for formalin administration. Fifty microliters
of dilute formalin (1%) was injected subcutaneously into the dorsal sur-
face of the right hind pawwith a 30-gauge needle. The animal was then
returned to the chamber for observation and nociceptive behavior was
observed immediately after formalin injection. A mirror was placed be-
hind the chamber to enable unhindered observation.Nociceptive behav-
ior was quantified as the numbers of flinches of the injected paw during
1-min periods every 5 min up to 60 min after injection. Flinching was
readily identified andwas characterized as a rapid and brief withdrawal
or flexing the injected paw. Formalin-induced flinching behavior is bi-
phasic; the initial acute phase (0–10 min) is followed by a relatively
short quiescent period, which is then followed by a prolonged tonic re-
sponse (15–60 min).
Assessment of the antinociceptive activity of HD in the rat formalin test
Rats received 20%DMSO(50 μl, the effect of 20%DMSOwasnot differ-
ent from that of saline on formalin-induced nociception) or increasing
doses of HD (10–100 μg/paw) 20 min before formalin injection into the
dorsal surface of the right hindpaw. Then,flinchingbehaviorwas assessed
for 1 h. Rats in all groups were tested for possible side effects such as re-
duction of righting, stepping, and corneal/pinna reflexes before and after
drug treatment as previously reported (Malmberg and Yaksh, 1992).
Analysis of the possible mechanism of action of HD on formalin-induced
nociception in rat
Rats received a s.c. injection (50 μl) of vehicle (sterile 0.9% saline
or 20% DMSO) or increasing doses of the selective CB1 and CB2 recep-
tor antagonists AM281 (0.3 and 30 μg/paw) and SR144528 (0.3 and
30 μg/paw), respectively, as well as the 5-HT receptor antagonist
methiothepin (0.03 and 0.3 μg/paw) or opioid receptor antagonist
naloxone (5 and 50 μg/paw) 35 min before formalin injection and
15 min before HD administration (100 μg/paw) into the dorsal sur-
face of the right hind paw. Then, flinching behavior was assessed for
1 h.
































Fig. 2. Time course of the flinching behavior observed after local peripheral administra-
tion of vehicle and HD (100 μg/paw) in rats submitted to the formalin test. Each value
represents the mean of at least 6 animals±S.E.M. * Significantly different with respect
to the vehicle (Pb0.05), determined by two-way ANOVA followed by Tukey's test.
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FAAH inhibition assay
FAAH activity was assayed in homogenates of female Sprague-
Dawley rat brain (minus cerebellum) as described previously (Boldrup
et al., 2004). Briefly, test compound or ethanol carrier (10 ml)were incu-
bated at 37 °C for 10 min with diluted homogenates (165 ml, in 10 mM
Tris–HCl–1 mM EDTA, pH 7.6) and 25 ml of a mixture of 16 mM non-
radioactive AEA (2 mM final assay concentration) containing trace
amounts of [3H]-AEA with the label in the ethanolamine side chain
(30–60 Ci/mmol) and 1%w/v fatty acid free bovine serumalbumin. Reac-
tions were terminated by putting the samples on an ice-bath followed by
the addition of 80 μl charcoal mixed with 320 μl of 0.5 M HCl. After vig-
orous vortexing followed by centrifugation, the radioactivity (corre-
sponding to the [3H]-ethanolamine produced as a result of the FAAH-
catalyzed breakdown of [3H]-AEA) found in aliquots (200 ml) of the
aqueous phase was determined by liquid scintillation counting with
quench correction. Blank values used buffer in place of homogenates. Re-
sults are expressed as % of concomitantly assayed vehicle controls.Drugs
1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholi-
nyl-1H-pyrazole-3-carboxamide (AM281), methiothepin mesylate and
naloxone hydrochloride were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Non-radioactive AEA and 5-(4-chloro-3-methylphenyl)-1
-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]
hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528) were purchased at
Cayman Chemical (Ann Arbor, Michigan, USA). [3H]-Anandamide was
obtained from American Radiolabeled Chemicals, Inc (St Louis, MO,
USA). All other substances were of analytical grade. AM281, SR144528
andHDweredissolved in 20%DMSO in saline solution. AEAwasdissolved
in ethanol. Methiothepin and naloxone were dissolved in saline.Data and statistical analysis
All in vivo experimental results are given as themean±S.E.M. of the
data obtained in 6 animals per group. Curves were constructed plotting
the number of flinches as a function of time. The area under the number
of flinches against time curve (AUC), an expression of the duration and
intensity of the effect, was calculated by the trapezoidal rule.
One- or two-way analysis of variance (ANOVA) followed by Tukey's
test was used to compare differences between treatments. Differences
were considered to reach statistical significance when Pb0.05.Results
Antinociceptive effect of HD
Subcutaneous injection of 1% formalin into the hindpaw produced
a biphasic flinching behavior. The first phase started immediately after
formalin injection and declined gradually in about 10 min. The second
phase initiated 15 min after formalin injection and it reached a maxi-
mum effect between 30 and 40 min declining gradually at about
60 min (Fig. 2). Fig. 2 depicts the time course of the antinociceptive effect
of HD in the formalin test at the greatest dose tested. Local peripheral ip-
silateral, but not contralateral, administration of HD (10–100 μg/paw)
significantly reduced (Pb0.05) the number of flinches in a dose-
dependent manner during the second phase of the formalin test
(Figs. 2 and 3). In contrast, HD was unable to significantly reduce the
AUC for phase 1 of the test (Figs. 2 and 3). Since no effect was observed
during phase 1, data regarding this phase in subsequent experiments
have not been presented here. No side effects were observed in any of
the studied groups of animals.Effects of AM251 and SR144528 on HD-induced peripheral antinociception
Local peripheral administration of the selective CB1 cannabinoid
receptor antagonist AM281 (30 μg/paw) and the CB2 cannabinoid recep-
tor antagonist/PPARα receptor antagonist SR144528 (30 μg/paw), re-
spectively, were unable to prevent formalin-induced nociception when
given on their own. In marked contrast, both drugs dose-dependently
(0.3–30 μg/paw) prevented HD-induced antinociception (100 μg/paw)
during phase 2 of the formalin test (Fig. 4).
Effect of methiothepin and naloxone on HD-induced peripheral
antinociception
The non-selective 5-HT receptor antagonist methiothepin (0.03–
0.3 μg/paw) aswell as the non-selective opioid receptor antagonist nal-
oxone (5–50 μg/paw) prevented in a dose-dependent manner HD
(100 μg/paw)-induced antinociception (Fig. 5). When given alone, the
highest dose of both antagonists did not affect formalin-induced
nociception.
Effect of HD upon FAAH activity in vitro
The ability of HD to inhibit FAAH was investigated using the
endocannabinoid anandamide (2 μM) as substrate. A significant albeit
modest inhibition was seen at the two greatest concentrations tested
(20 and 50 μM) (Fig. 6).
Discussion
Antinociceptive effect of HD
In this study we have found that local peripheral ipsilateral, but not
contralateral, administration of HD significantly reduces formalin-
induced nociception in rats. Our data extend previous observations show-
ing that systemic administration of HD inhibits acetic acid-induced and
thermal nociception in mice (Déciga-Campos et al., 2007), and demon-
strate that the local effect of HD on the second phase of the formalin
test can be blocked by AM281, SR144528, naloxone and methiothepin.
Taken together, data suggest that HD inhibits nociception in inflammato-
ry and nociceptive painmodels after local and systemic administration in
rats or mice. Thus, HD retains the useful analgesic properties of PEA,
which reduces nociceptive behavior induced by formalin (Jaggar et al.,
1998; Calignano et al., 1998, 2001; LoVerme et al., 2006), acetic acid
(Calignano et al., 2001) as well as capsaicin (Quartilho et al., 2003),
carragenan (Conti et al., 2002; Gutiérrez et al., 2007) andmild heat injury






































Fig. 3. Antinociceptive effect of the local peripheral administration of HD during the first
(A) and second phase (B) of the formalin test in rats. Data are expressed as the area under
the number of flinches against time curve (AUC). Bars are the means±S.E.M. for at least
six animals. * Significantly different (Pb0.05) from the vehicle group (Veh), as determined
by one-way ANOVA followed by Tukey's test. CL: Contralateral.
Fig. 4. Effect of the local peripheral administration of AM281 (AM, 0.3, 30 μg/paw) and
SR144528 (SR, 0.3, 30 μg/paw) on HD-induced antinociception in rats submitted to the
formalin test. Bars are the means±S.E.M. of 6 animals. *Pb0.05, significantly different
from the control group (Veh) and # significantly different from the HD (100 μg/paw)
group, as determined by one-way ANOVA followed by Tukey's test.
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chronic pelvic pain (Calabrò et al., 2010) and carpal tunnel syndrome
(Conigliaro et al., 2011) in man.
Thefinding that the CB1 cannabinoid receptor antagonist AM251 and
the CB2 cannabinoid antagonist/PPARα receptor antagonist SR144528
block the effects of HD in the formalin test clearly implicate an activation
of the endocannabinoid system in themechanism of action of HD. How-
ever, PEA and its analogues do not interact directly with CB receptors
(Vandevoorde et al., 2003), and so an indirectmechanism is presumably
operative here. Some possibilities are considered below.
Role of FAAH inhibition in the antinociceptive effects of HD
Intraplantar administration of the selective FAAH inhibitor URB597 to
sham-operated rats results in increased levels of the endocannabinoids
oleoyl ethanolamide (OEA), AEA and 2-AG in the hind paws (Jhaveri et
al., 2006). Given that both AEA (via CB1 cannabinoid receptors) and
2-AG (via CB2 cannabinoid receptors) are efficacious in the formalin
test when given locally to the hind paws of rats (Guindon et al., 2006,
2007), and that FAAH inhibitors reduce the behavioral and biochemical
consequences of formalin in this test (Lichtman et al., 2004; Sit et al.,
2007; Clapper et al., 2010; Thors et al., 2010), inhibition of FAAH could
in theory be involved in the action of HD. The compound, however, was
a rather weak inhibitor of FAAH in vitro, producing inhibition of AEA hy-
drolysis only at concentrations of 20 μMand higher. As a caveat, it should
be pointed out that solubility issues in the FAAH assay are problematical
with PEA analogues (Vandevoorde et al., 2003), so that the compound
may be more potent as an inhibitor of FAAH than is seen here. However,
HD is less potent than PEA (IC50 value 5 μM)when tested in the same in-
cubation conditions (Jonsson et al., 2006). In addition, a recent study
found that the FAAH inhibitor ST4070 increased brain levels of the
endocannabinoids PEA and AEA, but not 2-AG (Caprioli et al., 2012).We thus conclude that although it is possible that FAAH inhibition may
be involved in the mechanism of action of HD, other mechanisms are
probably of greater importance. An alternative, however, may be that
HD can inhibit other metabolic pathways of PEA and/or AEA and that
this may contribute to the effects seen here. The best candidate in this
respect is N-acylethanolamine-hydrolyzing acid amidase (Sun et al.,
2005). Relatively little work has been undertaken on the pharmacology
of this enzyme, but a recent report has shown that a selective inhibitor
of N-acylethanolamine-hydrolyzing acid amidase reduces carrageenan-
induced leukocyte infiltration in vivo (Solorzano et al., 2009). To our
knowledge, inhibitors of this enzyme have not been tested locally in
rats submitted to the formalin test.
“Entourage”, CB2 cannabinoid receptor-like and PPARα-mediated effects
of HD
In view of the lack of direct effect of PEA upon CB1 and CB2 cannabi-
noid receptors, the SR144528-sensitive effect of PEA in the formalin test
(Calignano et al., 1998) has been attributed to effects on an unidentified
CB2-like receptor and to an “entourage” effect whereby the PEA in-
creases the efficacy of endocannabinoids (review, see Lambert et al.,
2002). Some studies have reported the ability of PEA to negatively
Fig. 5. Effect of the local peripheral administration of methiothepin (Met; 0.03, 0.3 μg/paw)
and naloxone (NLX; 5, 50 μg/paw) on HD-induced antinociception in rats submitted to the
formalin test. Bars are the means±S.E.M. of 6 animals. *Pb0.05, significantly different from
the control group (Veh) and # significantly different from the HD (100 μg/paw) group,
as determined by one-way ANOVA followed by Tukey's test.





























Fig. 6. Inhibition of FAAH by HD in vitro. Bars are the mean±S.E.M. of 3 rates of hydro-
lysis of the FAAH substrate anandamide (AEA, 2 μM) expressed as % of vehicle controls.
*Pb0.05 versus control.
1292 J.E. Roa-Coria et al. / Life Sciences 91 (2012) 1288–1294modulatemast cells activation through CB2 cannabinoid receptors (Facci
et al., 1995; Mazzari et al., 1996; Cerrato et al., 2010), although other
authors have not seen such effects (Jonsson et al., 2001). Another candi-
date mechanism to produce antinociception is PPAR-α, which is present
in peripheral sensory neurons (LoVerme et al., 2006). It is involved in the
analgesic effects of PEA, andwhich acts synergistically with CB1 cannabi-
noid receptors to reduce pain (LoVerme et al., 2006; Russo et al., 2007;
Sagar et al., 2008).Wallace et al. (2007) reported that the beneficial effect
of the PEA analogue palmitoylallylamide was partially blocked by a
PPARα antagonist in the partial sciatic nerve injurymodel of neuropathic
pain, and a PPARα component of the antinociceptive effects of the FAAH
inhibitor URB597 has also been seen in a model of inflammatory pain
(Sagar et al., 2008). The possible participation of PPAR-α in the anti-
nociceptive effect of HD in the rat formalin test is currently under inves-
tigation in our laboratory.
Involvement of opioid receptors
Local peripheral administration of the non-selective opioid receptor
antagonist naloxone prevented antinociception induced by local HD.
These results suggest that HD produces its peripheral effect followingactivation of opioid receptors at the peripheral terminal of the sensory
neuron. We hypothesize that this effect is downstream of themobiliza-
tion of the endocannabinoid system by HD, given that systemic, spinal
or supraspinal administration of naloxone is able to block the antino-
ciceptive effect of anandamide and Δ9-tetrahydrocannabinol (Reche
et al., 1996; Haller et al., 2008), of the CB2 cannabinoid receptor-
selective agonist AM1421 (Ibrahim et al., 2005; Curto-Reyes et al.,
2010) and of the FAAH inhibitors URB59, OL135 and JNJ-161010
(Jhaveri et al., 2006; Chang et al., 2006; Karbarz et al., 2009) in experi-
mental pain models.
Involvement of serotonin receptors
HD-induced antinociceptionwas prevented by the non-selective 5-HT
receptor antagonist methiothepin. Since methiothepin is a high-affinity
5-HT1/2/6/7 receptor antagonist (Hoyer et al., 1994), data suggest that
these receptors could be involved in HD-induced local antinociception
in the formalin test, again presumably downstream of the effects on the
endocannabinoid system. If this downstream effect is local, themost like-
ly candidate peripheral receptor would be the 5-HT1 receptor, whose ac-
tivation is linked to local antinociception (Doak and Sawynok, 1997;
Granados-Soto et al., 2010), but not the 5-HT2/6/7 receptors as their local
activation is associated with pronociception (Rocha-González et al.,
2005; Castañeda-Corral et al., 2009; Nakajima et al., 2009). There may
be adifference as towhich5-HT receptor subtypes are recruited following
local and systemic activation of the endocannabinoid system, since sys-
temic cannabinoids interact with descending serotonergic pathways via
CB1-mediated mechanisms to produce antinociception involving spinal
5-HT7 and 5-HT2A receptors (Seyrek et al., 2010), and since activation of
spinal 5-HT2 (Sasaki et al., 2001), 5-HT3 (Sasaki et al., 2001) and 5-HT7
(Dogrul et al., 2009; Yanarates et al., 2010) receptors produce
antinociception. Further experiments are needed to determine which
5-HT systems are involved in the actions of HD.
Conclusion
Our results indicate that HD produces peripheral antinociception
in the formalin test. The antinociceptive effects of HD are prevented
by AM281 and SR144528 as well as by methiothepin and naloxone.
The effect of HD on FAAH in vitro could contribute at best in part to
the local effect of HD. Our data are consistent with the hypothesis
that HD may have potential as an analgesic in inflammatory pain.
Conflict of interest statement
We do not have conflict of interest.
1293J.E. Roa-Coria et al. / Life Sciences 91 (2012) 1288–1294Acknowledgements
This work was supported by the ESM-IPN (project SIP-20110653 to
MD-C), the Swedish Science ResearchCouncil (grant no. 12158,medicine,
to CJF) and the Research Funds of the Medical Faculty, Umeå University
(to CJF). The authors would like to thank Britt Jacobsson for technical as-
sistance in the FAAH experiments. This study is part of the B.Sc. disserta-
tion of José Eduardo Roa-Coria. During this work José Eduardo Roa-Coria
received the “Apoyo para estudiantes de Licenciatura” fellowship from
Conacyt. José Eduardo Roa-Coria is a Conacyt fellow.References
Boldrup L, Wilson SJ, Barbier AJ, Fowler CJ. A simple stopped assay for fatty acid amide
hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys
Methods 2004;60:171–7.
Bridges D, Ahmad K, Rice ASC. The synthetic cannabinoid WIN55,212-2 attenuates
hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol
2001;133:586–94.
Calabrò RS, Gervasi G, Marino S, Mondo PN, Bramanti P. Misdiagnosed chronic pelvic
pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide.
Pain Med 2010;11:781–4.
Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous
cannabinoids. Nature 1998;394:277–81.
Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty
acid amide, palmitylethanolamide. Eur J Pharmacol 2001;419:191–8.
Caprioli A, Coccurello R, Rapino C, Di Serio S, Di Tommaso M, Vertechy M, et al. The novel
reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid
brain levels and counteracts neuropathic pain in different animalmodels. J Pharmacol
Exp Ther 2012;342:188–95.
Castañeda-Corral G, Rocha-González HI, Araiza-Saldaña CI, Ambriz-Tututi M, Vidal-Cantú
GC, Granados-Soto V. Role of peripheral and spinal 5-HT6 receptors according to the
rat formalin test. Neuroscience 2009;162:444–52.
Cerrato S, Brazis P, dellaValleMF,Miolo A, PuigdemontA. Effects of palmitoylethanolamide
on immunologically induced histamine, PGD2 and TNFα release from canine skinmast
cells. Vet Immunol Immunopathol 2010;133:9-15.
Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, et al. Inhibition of fatty acid
amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol
2006;148:102–13.
Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, et al. Ananda-
mide suppresses pain initiation through a peripheral endocannabinoid mecha-
nism. Nat Neurosci 2010;13:1265–70.
Conigliaro R, Drago V, Foster PS, Schievano C, DiMarzo V. Use of palmitoylethanolamide in
the entrapment neuropathy of the median in the wrist. Minerva Med 2011;102:
141–7.
Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of
endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone
in a model of acute inflammation in the rat. Br J Pharmacol 2002;135:181–7.
Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, Baamonde A. Spinal and peripheral
analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models
of bone cancer-induced pain. Br J Pharmacol 2010;160:561–73.
Déciga-Campos M, Montiel-Ruiz RM, Navarrete-Vázquez G, López-Muñoz FJ. Palmitic
acid analogues exhibiting antinociceptive activity in mice. Proc West Pharmacol
Soc 2007;50:75–7.
Doak GJ, Sawynok J. Formalin-induced nociceptive behavior and edema: involvement
of multiple peripheral 5-hydroxytryptamine receptor subtypes. Neuroscience
1997;80:939–49.
Dogrul A, Ossipov MH, Porreca F. Differential mediation of descending pain facilitation
and inhibition by spinal 5-HT3 and 5-HT7 receptors. Brain Res 2009;1280:52–9.
Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a pe-
ripheral cannabinoid receptor with differential sensitivity to anandamide and
palmitoylethanolamide. Proc Natl Acad Sci U S A 1995;92:3376–80.
Farquhar-Smith WP, Jaggar SI, Rice ASC. Attenuation of nerve growth factor-induced
visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors. Pain 2002;97:
11–21.
Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, et al. The role of central and
peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids
in a model of neuropathic pain. Pain 2001;92:91-100.
Granados-Soto V, Argüelles CF, Rocha-González HI, Godínez-Chaparro B, Flores-Murrieta
FJ, Villalón CM. The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F se-
rotonergic receptors in the reduction of nociception in rats. Neuroscience 2010;165:
561–8.
Guindon J, De Léan A, Beaulieu P. Local interactions between anandamide, an endo-
cannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflam-
matory pain. Pain 2006;121:85–93.
Guindon J, Desroches J, Beaulieu P. The antinociceptive effects of intraplantar injections of
2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol
2007;150:693–701.
Gutiérrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. Activation of pe-
ripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflam-
matory nociception: a comparative analysis. Br J Pharmacol 2007;150:153–63.Haller VL, Stevens DL, Welch SP. Modulation of opioids via protection of anandamide
degradation by fatty acid amide hydrolase. Eur J Pharmacol 2008;600:50–8.
HoyerD, ClarkeDE, Fozard JR,Hartig PR,MartinGR,Mylecharane EJ, et al. InternationalUnion
of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Pharmacol Rev 1994;46:157–203.
Ibrahim M, Porreca F, Lai J, Albrecht P, Rice F, Khodorova A, et al. CB2 cannabinoid re-
ceptor activation produces antinociception by stimulating peripheral release of en-
dogenous opioids. Proc Natl Acad Sci U S A 2005;102:3093–8.
Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabi-
noid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in
visceral and somatic inflammatory pain. Pain 1998;76:189–99.
Jhaveri MD, Richardson D, Kendall DA, Barret DA, Chapman V. Analgesic effects of fatty
acid amide hydrolase inhibition in a rat model of neurophatic pain. J Neurosci
2006;26:13318–27.
Johanek LM, Simone DA. Activation of peripheral cannabinoid receptors attenuates cu-
taneous hyperalgesia produced by a heat injury. Pain 2004;109:432–42.
Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ. Effects of homologues and
analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid
anandamide. Br J Pharmacol 2001;133:1263–75.
Jonsson KO, Persson E, Fowler CJ. The cannabinoid CB2 receptor selective agonist
JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but
not the release of beta-hexosaminidase from skin slices in vitro. Life Sci 2006;78:
598–606.
Karbarz M, Luo L, Chang L, Tham C, Palmer J, Wilson S, et al. Biochemical and biological
properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid
phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth
Analg 2009;108:316–29.
Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, et al. A cannabi-
noid agonist differentially attenuates deep tissue hyperalgesia in animal models of
cancer and inflammatory muscle pain. Pain 2003;103:175–86.
Lambert D, Vandevoorde S, Jonsson K, Fowler J. The palmitoylethanolamide family: a
new class of anti-inflammatory agents? Curr Med Chem 2002;9:663–74.
Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. Revers-
ible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for
an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther
2004;311:441–8.
LoVerme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor
peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory
actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15–9.
LoVerme J, Russo R, La RanaG, Fu J, Farthing J,Mattace-Raso G, et al. Rapid broad-spectrum
analgesia through activation of peroxisome proliferator-activated receptor-alpha.
J Pharmacol Exp Ther 2006;319:1051–61.
Malmberg AB, Yaksh TL. Antinociceptive actions of spinal nonsteroidal antiinflam-
matoryagents on the formalin test in the rat. J Pharmacol Exp Ther 1992;263:136–46.
Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecamide
is orally active in reducing edema formation and inflammatory hyperalgesia by
down-modulating mast cell activation. Eur J Pharmacol 1996;300:227–36.
Nakajima K, Obata H, Ito N, Goto F, Saito S. The nociceptive mechanism of
5-hydroxytryptamine released into the peripheral tissue in acute inflammatory
pain in rats. Eur J Pain 2009;13:441–7.
Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, et al. Inhi-
bition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid
receptors. Anesthesiology 2003;99:955–60.
Reche I, Fuentes JA, Ruiz-Gayo M. Potentiation of Δ9-tetrahydrocannabinol-induced
analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors.
Eur J Pharmacol 1996;318:11–6.
Rocha-González HI, Meneses A, Carlton SM, Granados-Soto V. Pronociceptive role of
peripheral and spinal 5-HT7 receptors in the formalin test. Pain 2005;117:
182–92.
Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, et al. The fatty acid amide
hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl
ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp
Ther 2007;322:236–42.
Sagar DR, Kendall DA, Chapman V. Inhibition of fatty acid amide hydrolase produces
PPAR-α-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol
2008;155:1297–306.
Sasaki M, Ishizaki K, Obata H, Goto F. Effects of 5-HT2 and 5-HT3 receptors on the mod-
ulation of nociceptive transmission in rat spinal cord according to the formalin test.
Eur J Pharmacol 2001;424:45–52.
Scott DA, Wright CE, Angus JA. Evidence that CB1 and CB2 cannabinoid receptors medi-
ate antinociception in neuropathic pain in the rat. Pain 2004;109:124–31.
Seyrek M, Kahraman S, Deveci MS, Yesilyurt O, Dogrul A. Systemic cannabinoids pro-
duce CB1-mediated antinociception by activation of descending serotonergic path-
ways that act upon spinal 5-HT7 and 5-HT2A receptors. Eur J Pharmacol 2010;649:
183–94.
Sit S, Conway C, Bertekap R, Xie K, Bourin C, Burris K, et al. Novel inhibitors of fatty acid
amide hydrolase. Bioorg Med Chem Lett 2007;17:3287–91.
Smith FL, Fujimori K, Lowe J, Welch SP. Characterization of Δ9-tetrahydrocannabinol
and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol
Biochem Behav 1998;60:183–91.
Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, et al. Selective
N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for en-
dogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A
2009;106:20966–71.
Sun YX, Tsuboi K, Zhao LY, Okamoto Y, Lambert DM, Ueda N. Involvement of
N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide
1294 J.E. Roa-Coria et al. / Life Sciences 91 (2012) 1288–1294and other N-acylethanolamines in macrophagues. Biochim Biophys Acta 2005;1736:
211–20.
Thors L, Burston JJ, Alter BJ, McKinney MK, Cravatt BF, Ross RA, et al. Biochanin A, a nat-
urally occurring inhibitor of fatty acid amide hydrolase. Br J Pharmacol 2010;160:
549–60.
Vandevoorde S, Jonsson K-O, Fowler CJ, Lambert DM. Modifications of the ethanol-
amine head in N-palmitoylethanolamine: synthesis and evaluation of new
agents interfering with the metabolism of anandamide. J Med Chem 2003;46:
1440–8.Wallace VC, Segerdahl A, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, et al. The
effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain
behaviour in rodent models of neuropathy. Br J Pharmacol 2007;151:1117–28.
Yanarates O, Dogrul A, Yildirim V, Sahin A, Sizlan A, Seyrek M, et al. Spinal 5-HT7 recep-
tors play an important role in the antinociceptive and antihyperalgesic effects of
tramadol and its metabolite, O-desmethyltramadol, via activation of descending
serotonergic pathways. Anesthesiology 2010;112:696–710.
Zimmerman M. Ethical guidelines for investigations of experimental pain in conscious
animals. Pain 1983;16:109–10.
